Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
The price spiked because lots of less-than-savvy robinhood users mistakenly bought shares in TLSA thinking it was TSLA. it may well be that the ADR news brought our ticker into public view so it may well have been the root cause. They were sold reasonably quickly once the mistake was realised, hence the sharp up and down to the peak.
https://markets.businessinsider.com/news/stocks/tesla-stock-tiziana-ticker-confusion-potentially-benefiting-biotech-company-mixup-2020-7
However you look at it it was a false spike and really oughtn't be referred to as the share's high spot, even though technically it was.
It isn't down from 300, that was a false extreme spike caused by the robinhood users in the US confusing the Tesla ticker (TSLA) with the US ADR ticker (TLSA).
That's not to say TILS won't reach 300p or more at some point, but I would suggest the more realistic top price to comare it to is somewhere around 200, if you exclude that spike
What's that got to do with it? Are you an Accustem denyer?
I wouldn't make any assumption about goods news based on the green box count. Still, each to his own.
My memory tells me that there was something said that they were transferring StemPrintER development out to Italy (was it to a university?) but I don't recall them saying that it would be stalled.
From https://www.investopedia.com/ask/answers/06/adrvsads.asp
An American depositary receipt (ADR) allows foreign companies to list their shares on U.S. stock exchanges.
An American depositary share (ADS) is the U.S. dollar-denominated equity share of a foreign-based company available for purchase on an American stock exchange.
The entire issuance is called an American Depositary Receipt (ADR), and the individual shares are referred to as ADS.
I think the nub is whether the quoted price we are seeing is for one actual share or one ADx, whatever two shares is called, which is two shares.
If you look up TLSA share price it is showing the ADR price not the individual share price, as we know a TILS share is not worth the value shown. https://www.cnbc.com/quotes/tlsa?qsearchterm=tlsa
So it doesn't seem unreasonable to assume that if you look up Accustem on the same platform it will also be showing the ADR price. https://www.cnbc.com/quotes/ACMSY - i.e. a share is worth half that value (currently $0.44 so $0.22 approx 15.7p)
Yes Cloudy, thanks.
So the reported price was $0.40 at close. That's per ADR right? In which case $0.20 per share, a bit over 14p.
Yes absolutely though given that there is a commonality in the management and ownership and for max publicity it wouldn't surprise me if there was a bit of cross-fertilisation of good news.
Why not an RNS? It's a UK company, just not traded on the UK markets.
Yes I remember now, OTC doesn't have the NASDAQ requirements and is widely used for foreign companies to trade in the US. I suppose it's a junior market and once a company can qualify under one of the NASDAQ definitions it could, I suppose, graduate - but presumably still trading in ADRs as it remains a foreign owned company.
I don't think the qualifications for trading on OTC are very high at all - no history etc, so I suspect the prices we can see are actual traded prices.
I'm pretty sure I read somewhere that they used an inhaled interferon in the early days.
We're quite a bit ahead of them in the trials then.
Maybe we should get our product on Sky somehow, as a better completitor.
Cloudy we've been round this one in depth twice recently to my knowledge. They don't meet any of the requirements as far as I remember but then Accustem shares are not being listed on the NASDAQ as such, but ADRs are - and I think I ended up thinking that must be the loophole which precludes them from the listing requirements. ISTR someone found some categories which bypass them anyway.
For sure Accustem won't have a trading history for maybe years as right now we have no products...
"Accustem as a new entity has to have trading history before Nasdaq will let it on,"
How does that work then? Or were you talking about LSE forums?
I don't for one minute agree with what Ragz has said but I also can't see how you know the background of previous and current shareholders. It's very flattering to say we are all well-researched but I suspect that 1) some aren't and 2) that's always been the case. In fact the very early birds may have been the best informed, as most of us have really only become aware of this sector in much detail since the pandemic whereas some were invested before it appeared.
If you review Ragz history, he was in this share possibly long before you were and sold at around the £2.20 mark so I feel you are doing him something of a disservice (he said at 14 Oct 2020 17:52 he "sold the other day"). I think tarring all the earlier investors with a slightly offensive brush is unnecessary as well as being incorrect, although you are undoubtedly correct that there has been quite a few people trading rather than investing - but I think that's always true in many stocks, and many make a good living at it.
I'm not sure that SNG were "late to the party " as Ragz asserts, more that the party is going on rather longer than people might have expected. Despite what they may say, I expect that most invested here are hoping for a "multi bagger", and won't be hanging around for altruistic reasons if that target is achieved.
My personal view is that while Synairgen are pretty much "going it alone" for lots of good reasons, which I expect and hope will work out very well, a tie-up of sorts with a major earlier on may have opened other doors and brought a raft of expertise and resource which may well have accelerated the outcome. But I am delighted with what I see and read about progress and am now tuned in to not really having much firm info until much later in the year. Anything earlier is a bonus, for me.
What Ragz is missing of course is that vaccines alone won't suffice, and that if SNG get approval for Covid then there is other massive markets will open up to them, like the COPD one which this research was founded on, but maybe even down to flu. And while this pandemic might appear to be receding, I don't think it is, and whether or not it is, Governments around the world will be looking for "general purpose" answers to stockpile in anticipation of a similar happening in future.
Not something I've been aware of, please let me know where could I see that?
Mostly all research reported on LSE is there for all to see. Not many bother. So it does no harm for someone to pick up on a piece of relevant info and pass comment on it.
I really can't be bothered arguing with you but although it's there for all to see, I will point out that your percentage of trolling posts and personal attacks is much higher than mine whereas the number of interesting discussions you have initiated on relevant matters is considerably lower.
Have a nice day.
I expect there are good technical reasons (which might include just being a crappy app at their end) why they can't do that, otherwise I'm sure it would have been done.
Hardly seem worth the effort of complaining. They haven't denied ownership of the shares after all.
Are you suggesting that I'm a doomer/gloomer?
If so, I'm not.
But at least I posted a researched post about something I found potentially intriguing which may be of interest to others, rather than take the easy option of just sitting back and knocking what someone else said.
I looked a bit deeper into one of last week’s director buys.
Mr Koch's (non-exec chairman) rather modest purchase took his holding to about 16% of the company, 446m shares. For some reason they quote the purchase price in USD but I'm guessing that purchase was at the prevailing market rate, so he is down a few bob on that one, but I expect much of his holding was bought at much lower costs. He was appointed in July 2019 so has built up the stake pretty quickly. (A trawl through the RNSs should help, if anyone is interested).
So either it really is a Good Thing, in which case he is topping up with his pocket money, or is a window dressing move (alongside the much smaller one by the FD) to try to restore shareholder confidence.
Make of it what you will.
Woo hoo - don't mind admitting I was wrong, showing as 9% up on my app atm :-)